HomeProductsBuilding BlocksHeterocyclic ScaffoldsTriazolesLetrozole
Chemical structure of CAS 112809-51-5

Letrozole

CAS No.112809-51-5
MDL No.MFCD00866241
MFC17H11N5
MW285.30
InChI KeyHPJKCIUCZWXJDR-UHFFFAOYSA-N
CUSTOM SYNTHESISPRECLINICAL SUPPORT

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

Letrozole is a triazole nitrile with antineoplastic activity as an aromatase (EC 1.14.14.14) inhibitor.

CAS No.112809-51-5
Product NameLetrozole

Biological Targets

CYP19A1

Associated Conditions

Growth delay·metastasis·azoospermia·polycystic ovary syndrome·ovarian hyperstimulation syndrome·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Update on endocrine aspects of breast cancer: report from the 23rd San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, 6-9 December 2000.

Breast cancer research : BCR • Vol. 3, Issue 3 • 2001
PMID: 11305952PMC: PMC138682DOI: 10.1186/bcr292

FDA panel recommends two new cancer drugs for approval.

Journal of the National Cancer Institute • Vol. 93, Issue 3 • 2001
PMID: 11158184DOI: 10.1093/jnci/93.3.175

Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate.

Fertility and sterility • Vol. 75, Issue 2 • 2001
PMID: 11172831DOI: 10.1016/s0015-0282(00)01705-2

From the Food and Drug Administration.

JAMA • Vol. 285, Issue 9 • 2001
PMID: 11231734

Documentation